Quantcast

Cytomegalovirus: First CMV Education Program in US to Help Protect Fetuses; polyDNA Recommends Preparing for Pregnancy with Gene-Eden-VIR

July 25, 2013

“Approximately one in five children with congenital CMV infection will develop permanent problems, such as hearing loss or developmental disabilities" according to an article published on July 12, 2013 in The Standard Examiner (1). polyDNA recommends cleansing the future parents’ bodies from viruses which may harm the baby.

Rochester, NY (PRWEB) July 25, 2013

Women worried about having a healthy baby should ask their home states to copy the health initiative recently adopted by the state of Utah. This state has become the first in the United States “to launch an education and screening campaign for a common virus known as (cytomegalovirus) CMV.”

Dr. Stephanie McVicar from the Utah Department of Health said that “About 40 percent of women who become infected with CMV for the first time during a pregnancy will pass the infection to their fetus. CMV is the leading cause of nongenetic hearing loss in children.”(1)

This information must be brought to the attention of couples who want to begin having children because “CMV …is a preventable virus.” (1) In fact, it is “the most common virus that no one has heard of.” (1)

“In addition, McVicar said, congenital CMV infection causes more long-term health problems and childhood deaths than Down syndrome, fetal alcohol syndrome, neural tube defects and pediatric HIV/AIDS.”

The Human Cytomegalovirus is generally passed from infected people to others through direct contact with body fluids, such as urine or saliva.

The American Pregnancy Association says that “Maternal CMV infections may be treated with immune boosting drugs.” (2) However, these drugs are limited by their side effects, and the fact that they are only moderately effective according to a study published in 2000 in the journal Current Opinion in Investigational Drugs. (3)

Thus, polyDNA suggests an alternative method in preventing CMV transmission from mothers to fetuses. Before a couple attempts to become pregnant, both partners should cleanse their body of viruses that may harm the baby.

Couples should take Gene-Eden-VIR, a natural CMV remedy to help the immune system clear the virus from their bodies. Once clear of the virus, the risk of transmission will be eliminated.

Gene-Eden-VIR is designed to fight against the latent CMV. A recent post marketing clinical study showed that Gene-Eden-VIR is safe and effective. Up to 70% of those studied reported a decrease in viral symptoms. (4)

Each ingredient of Gene-Eden-VIR was chosen through a scientific approach. Scientists scanned thousands of scientific and medical papers published in various medical and scientific journals around the world to identify the safest, most effective natural ingredients that target the latent form of CMV. (5)

To learn more about Gene-Eden-VIR, visit http://www.gene-eden-kill-virus.com. All orders of Gene-Eden-VIR are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

References:

(1)    http://www.standard.net/stories/2013/07/11/utah-screening-virus-can-cause-disabilities-infants

(2)    http://americanpregnancy.org/pregnancycomplications/cytomegalovirusinfection.html

(3)    http://www.ncbi.nlm.nih.gov/pubmed/18246516

(4)    cbcd.net/Gene-Eden-VIR-Clinical-Study.php

(5)    buygeneeden.com/studies.php

polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr. Hanan Polansky, which is based on Computer Intuition.

In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery, called Microcompetition with Foreign DNA. The discovery explains how foreign DNA fragments, and specifically, DNA of latent viruses, cause most major diseases.

polyDNA developed Gene-Eden-VIR , an antiviral natural remedy that helps the immune system kill latent viruses.

For the original version on PRWeb visit: http://www.prweb.com/releases/2013/7/prweb10954829.htm


Source: prweb



comments powered by Disqus